
Beam Therapeutics Inc.
BEAMAnalyst Consensus
Price Target Trend
Rating Trend
Recent Price Targets
| Date | Firm | Analyst | Target | Price Then | Source |
|---|---|---|---|---|---|
| Oct 29, 2026 | Canaccord Genuity | $79.00(+174%) | $28.78 | TheFly | |
| May 21, 2026 | H.C. Wainwright | Patrick Trucchio | $80.00(+195%) | $27.11 | StreetInsider |
| May 13, 2026 | Tudor Pickering | William Pickering | $39.00(+23%) | $31.58 | TheFly |
| Feb 25, 2026 | RBC Capital | $26.00(-16%) | $30.83 | TheFly | |
| Feb 20, 2026 | Canaccord Genuity | $74.00(+165%) | $27.88 | TheFly | |
| Jan 21, 2026 | Tudor Pickering | William Pickering | $41.00(+32%) | $31.00 | StreetInsider |
| Jan 20, 2026 | Bernstein | $41.00(+32%) | $30.96 | TheFly | |
| Jan 7, 2026 | UBS | Michael Yee | $28.00(-1%) | $28.34 | StreetInsider |
| Nov 24, 2025 | Evercore ISI | $35.00(+50%) | $23.32 | TheFly | |
| Oct 9, 2025 | Jefferies | $41.00(+47%) | $27.86 | TheFly | |
| May 7, 2025 | Guggenheim | Debjit Chattopadhyay | $55.00(+244%) | $15.99 | TheFly |
| Mar 3, 2025 | Scotiabank | $25.00(-0%) | $25.10 | TheFly | |
| Jan 7, 2025 | Tudor Pickering | William Pickering | $37.00(+37%) | $27.08 | StreetInsider |
| Nov 6, 2024 | Leerink Partners | Rick Bienkowski | $39.00(+60%) | $24.34 | StreetInsider |
| Nov 5, 2024 | BMO Capital | Kostas Biliouris | $57.00(+134%) | $24.34 | StreetInsider |
| Sep 11, 2024 | Stifel Nicolaus | Benjamin Burnett | $69.00(+196%) | $23.34 | StreetInsider |
| Feb 1, 2023 | Cantor Fitzgerald | $62.00(+43%) | $43.45 | Benzinga | |
| Dec 20, 2022 | BMO Capital | Kostas Biliouris | $66.00(+59%) | $41.59 | StreetInsider |
| Dec 13, 2022 | Citigroup | $62.00(+29%) | $48.19 | Benzinga | |
| Apr 28, 2022 | Credit Suisse | $62.00(+56%) | $39.83 | Benzinga |
Recent Rating Actions
| Firm | Action | Rating | Date |
|---|---|---|---|
| Guggenheim | maintain | Buy | Nov 5, 2026 |
| Canaccord Genuity | maintain | Buy | Nov 4, 2026 |
| Wedbush | maintain | Outperform | Nov 4, 2026 |
| Canaccord Genuity | maintain | Buy | Oct 29, 2026 |
| Wedbush | maintain | Outperform | Oct 28, 2026 |
| HC Wainwright & Co. | maintain | Buy | Oct 15, 2026 |
| Wedbush | maintain | Outperform | Oct 14, 2026 |
| Wedbush | maintain | Outperform | Sep 9, 2026 |
| HC Wainwright & Co. | maintain | Buy | Aug 25, 2026 |
| B of A Securities | maintain | Buy | Jul 8, 2026 |
| HC Wainwright & Co. | maintain | Buy | Jul 7, 2026 |
| Bernstein | maintain | Outperform | May 13, 2026 |
| Citigroup | maintain | Buy | Mar 26, 2026 |
| Wedbush | maintain | Outperform | Feb 25, 2026 |
| RBC Capital | maintain | Sector Perform | Feb 25, 2026 |
| Bernstein | maintain | Outperform | Jan 21, 2026 |
| HC Wainwright & Co. | maintain | Buy | Oct 10, 2025 |
| JP Morgan | maintain | Overweight | Oct 9, 2025 |
| HC Wainwright & Co. | maintain | Buy | Sep 15, 2025 |
| Barclays | maintain | Equal Weight | Aug 6, 2025 |
| Guggenheim | maintain | Buy | May 7, 2025 |
| Wells Fargo | maintain | Overweight | May 7, 2025 |
| Barclays | maintain | Equal Weight | May 7, 2025 |
| HC Wainwright & Co. | maintain | Buy | Apr 7, 2025 |
| B of A Securities | upgrade | Neutral →Buy | Mar 28, 2025 |
Earnings History
Next report: Feb 23, 2027 · EPS est. $-1.29| Report Date | EPS Actual | EPS Est. | Revenue Actual | Revenue Est. |
|---|---|---|---|---|
| Nov 3, 2026 | $-1.28 | $-1.15 | $307.0K | $8.8M |
| Aug 4, 2026 | $-1.18 | $-1.11 | $490.0K | $16.4M |
| May 7, 2026 | $-0.91 | $-0.87 | $31.7M | $11.0M |
| Feb 24, 2026 | $-0.10 | $-1.13 | $114.1M | $11.7M |
| Nov 4, 2025 | $-1.10 | $-0.98 | $9.7M | $13.2M |
| Aug 5, 2025 | $-1.00 | $-1.04 | $8.5M | $11.5M |
| May 6, 2025 | $-1.24 | $-1.11 | $7.5M | $15.5M |
| Feb 25, 2025 | $-1.09 | $-1.25 | $30.1M | $16.5M |
News
BEACON Trial Results Selected for Official ASH Press Program Initial Patient-Reported Outcomes Demonstrate Early and Sustained Improvements in Physical Function, Pain, Fatigue, Emotional and Social Well-Being and Symptom Severity U.S. Biologics License Application (BLA) Submission for Risto-cel Expected as Early as Year-End 2026 CAMBRIDGE, Mass., Nov. 04, 2026 (GLOBE NEWSWIRE) -- Beam Therapeutics Inc. (Nasdaq: BEAM), a biotechnology company developing precision genetic medicines through base ed…
Beam Therapeutics Inc. (BEAM) came out with a quarterly loss of $1.28 per share versus the Zacks Consensus Estimate of a loss of $1.17. This compares to a loss of $1.1 per share a year ago.
Updated BEAM-302 Phase 1/2 Clinical Data Presented at ERS Demonstrated Durable Increases in Functional AAT and Reductions in Mutant Z-AAT; Completion of Dosing in the Global Pivotal Cohort Expected in First Half of 2027
Genomics and synthetic biology are transforming healthcare through precision medicine and gene editing, putting ILMN, QURE and TXG in focus as the markets expand.
Beam Therapeutics (BEAM) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.
Beam Therapeutics Inc. (BEAM) Reviews Initial Phase I II BEAM-301 Data in Glycogen Storage Disease Type 1a Transcript
Beam Therapeutics NASDAQ: BEAM reported initial clinical data from its Phase I/II trial of BEAM-301, an investigational base-editing therapy for glycogen storage disease type 1A (GSD1a), showing dose-dependent improvements in fasting tolerance and reductions in cornstarch supplementation among the first six treated patients.
In the 40 mg Cohort, Two Patients Achieved 15 Hours of Controlled Fasting, Improvements in Glucose Control and No Longer Required Starch Supplementation Following Treatment Safety Profile of BEAM-301 Consistent with LNP-Based Therapies Beam Plans to Engage FDA on Potential Path to Approval; Enrollment in 60 mg Dose Cohort Underway Company to Host Investor Webcast Today, October 27, 2026, at 8:00 a.m. ET CAMBRIDGE, Mass.
Beam Therapeutics Inc. (NASDAQ: BEAM - Get Free Report) CEO John Evans sold 25,000 shares of the business's stock in a transaction dated Thursday, October 15th. The stock was sold at an average price of $23.57, for a total transaction of $589,250.00. Following the sale, the chief executive officer owned 1,047,205 shares in the company, valued
Cathie Wood owns Beam shares worth roughly $220 million, at the stock's current price. All of the company's revenue is collaboration revenue.
NEW YORK, Oct. 15, 2026 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Beam Therapeutics Inc. ("Beam" or the "Company") (NASDAQ: BEAM). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext.
NEW YORK, Oct. 13, 2026 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Beam Therapeutics Inc. (“Beam” or the “Company”) (NASDAQ: BEAM). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980.
Short sellers are betting heavily against 10 stocks, and the fuse is getting shorter. Each one has more than 38% of its float sold short, with market caps above $2 billion and average daily volume above 1 million shares, according to Benzinga Pro screener data as of Oct. 12.
BEAM-301 Achieves Clinical Proof of Concept for Genetic Correction of R83C Mutation in GSDIa Initial Phase 1/2 Data Show Restoration of Endogenous Glucose Production Following a Single Treatment, with Dose-Dependent Improvements in Key GSDIa Endpoints Safety Profile of BEAM-301 Consistent with LNP-based Therapies Beam to Host Investor Webcast on Tuesday, October 27, 2026, at 8:00 a.m. ET CAMBRIDGE, Mass.
NEW YORK, Oct. 8, 2026 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Beam Therapeutics Inc. ("Beam" or the "Company") (NASDAQ: BEAM). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext.
NEW YORK, Oct. 06, 2026 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Beam Therapeutics Inc. (“Beam” or the “Company”) (NASDAQ: BEAM). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980.
NEW YORK, Oct. 1, 2026 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Beam Therapeutics Inc. ("Beam" or the "Company") (NASDAQ: BEAM). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext.
NEW YORK, Sept. 29, 2026 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Beam Therapeutics Inc. (“Beam” or the “Company”) (NASDAQ: BEAM). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980.
Beam Therapeutics is reaffirmed as a long-term buy, with significant upside expected around 2028–2029 as BEAM-302 advances. BEAM's pipeline leadership in AATD gene editing (BEAM-302) offers first-mover advantage, while Risto-cel's blockbuster potential is now downgraded. AI-driven competition, such as Anthropic, is unlikely to disrupt BEAM in the near term; partnerships with AI firms could become a future catalyst.
Ten stocks worth more than $2 billion each have more than a third of their float sold short. At the top of the list, one company has more than 80% of its float sold short.